Key Takeaways
- • Chinook Investment Partners completed a growth investment in PractiVet on April 29, 2026, targeting a leading branded supplier of veterinary infusion devices and IV consumables serving thousands of U.S. veterinary hospitals and teaching institutions.
- • PractiVet operates with more than 30,000 infusion devices deployed across specialty, emergency, and academic veterinary settings, positioning it as a scaled player in a niche but essential animal health sector.
- • McGuireWoods LLP served as legal counsel to Chinook on the transaction, while Dorsey & Whitney LLP represented PractiVet; transaction terms were not disclosed.
- • PractiVet will continue operations under its existing brand and leadership team, with CEO Richard Costello emphasizing the company's focus on clinical excellence, patient outcomes, and clinician safety as differentiators in the veterinary critical care market.
- • The investment aligns with Chinook's stated strategy of partnering with entrepreneurial founders and management teams to build scaled, sustainable, market-leading businesses in essential and niche American sectors.
Summary
Chinook Investment Partners, a Colorado-based private equity firm, announced completion of a growth investment in PractiVet, a veterinary medical device company founded in 2007. The transaction closed on April 29, 2026, and represents Chinook's continued focus on essential healthcare niches and partnership-oriented capital deployment.
PractiVet specializes in branded infusion and syringe pump devices alongside IV infusion set consumables for veterinary applications. The company has achieved meaningful scale within its target market, with more than 30,000 infusion devices currently deployed across specialty hospitals, emergency clinics, general practice facilities, and academic veterinary institutions throughout the United States. According to Richard Costello, PractiVet's CEO, the company's competitive positioning rests on clinical excellence, customized product design, and workflow efficiency—factors that support adoption among leading veterinary care providers nationwide.
Under Chinook's ownership, PractiVet will maintain its existing brand identity and management structure while pursuing expanded market leadership in veterinary critical care solutions. McGuireWoods LLP provided legal counsel to Chinook on the transaction, with Dorsey & Whitney LLP representing PractiVet. The specific valuation and transaction terms were not disclosed in the announcement.
The investment reflects Chinook's broader thesis around building durable market positions within specialized sectors of the U.S. economy. By maintaining PractiVet's operational independence and leadership continuity, the structure prioritizes alignment with the existing management team—a hallmark of Chinook's partnership-focused investment approach.
PractiVet specializes in branded infusion and syringe pump devices alongside IV infusion set consumables for veterinary applications. The company has achieved meaningful scale within its target market, with more than 30,000 infusion devices currently deployed across specialty hospitals, emergency clinics, general practice facilities, and academic veterinary institutions throughout the United States. According to Richard Costello, PractiVet's CEO, the company's competitive positioning rests on clinical excellence, customized product design, and workflow efficiency—factors that support adoption among leading veterinary care providers nationwide.
Under Chinook's ownership, PractiVet will maintain its existing brand identity and management structure while pursuing expanded market leadership in veterinary critical care solutions. McGuireWoods LLP provided legal counsel to Chinook on the transaction, with Dorsey & Whitney LLP representing PractiVet. The specific valuation and transaction terms were not disclosed in the announcement.
The investment reflects Chinook's broader thesis around building durable market positions within specialized sectors of the U.S. economy. By maintaining PractiVet's operational independence and leadership continuity, the structure prioritizes alignment with the existing management team—a hallmark of Chinook's partnership-focused investment approach.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.